Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants

home / between-the-lines / nirsevimab-for-prevention-of-rsv-in-healthy-late-preterm-and-term-infants

Experts discuss the recently FDA-approved nirsevimab for the prevention of Respiratory Syncytial Virus (RSV) for late-preterm and term infants, highlighting a recent study on the safety and efficacy of nirsevimab.

© 2024 MJH Life Sciences

All rights reserved.